Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41933595.
- Also identified by DOI 10.1016/j.radonc.2026.111519.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We evaluated acute toxicity and disease control in 42 patients receiving thoracic radiotherapy with concurrent KRAS G12C inhibitors. Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis. There were no significant differences in toxicity between patients who held versus continued inhibitors during radiotherapy. The estimated cumulative incidence of local failure at 6 months was 5%.